Radiopharm Theranostics Future Growth
Future criteria checks 4/6
Radiopharm Theranostics is forecast to grow earnings and revenue by 45.3% and 50.1% per annum respectively. EPS is expected to grow by 9.5% per annum. Return on equity is forecast to be 45.5% in 3 years.
Key information
45.3%
Earnings growth rate
9.5%
EPS growth rate
| Biotechs earnings growth | 14.9% |
| Revenue growth rate | 50.1% |
| Future return on equity | 45.5% |
| Analyst coverage | Low |
| Last updated | 25 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 122 | 17 | -10 | 16 | 3 |
| 6/30/2026 | 16 | -41 | -42 | -38 | 4 |
| 6/30/2025 | N/A | -53 | -58 | -55 | 4 |
| 6/30/2024 | 2 | -48 | -23 | -23 | N/A |
| 3/31/2024 | 4 | -47 | -24 | -23 | N/A |
| 12/31/2023 | 6 | -47 | -24 | -23 | N/A |
| 9/30/2023 | 6 | -41 | -25 | -23 | N/A |
| 6/30/2023 | 6 | -35 | -25 | -23 | N/A |
| 3/31/2023 | 5 | -30 | -21 | -20 | N/A |
| 12/31/2022 | 4 | -26 | -18 | -17 | N/A |
| 9/30/2022 | 2 | -28 | -28 | -14 | N/A |
| 6/30/2022 | N/A | -30 | -38 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: RAD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RAD is expected to become profitable in the next 3 years.
Revenue vs Market: RAD is forecast to have no revenue next year.
High Growth Revenue: RAD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RAD's Return on Equity is forecast to be very high in 3 years time (45.5%).